#TP53
🧬 #ASH26 #Weekend_Review #TP53-mt MN

Several evolving themes: allelic state & LOH, disease heterogeneity, transplant, immune biology &emerging therapeutic vulnerabilities.

Also excited to share our work on #PPM1D, #DDX41, and a better prognostic TP53 subset from the #COMMAND_consortium.
November 15, 2026 at 5:19 AM
Data on p53 antibodies are also available via Only Good Antibodies platform: onlygoodantibodies.co.uk/antibodies/T...
🧪
TP53 antibody characterisation — knockout-controlled results for 31 antibodies | Only Good Antibodies
Knockout-controlled characterisation data for 31 TP53 (also known as P53) antibodies tested across WB, IP, ICC-IF and IHC. Free to access via Only Good Antibodies (OGA).
onlygoodantibodies.co.uk
November 15, 2026 at 10:35 AM
Our PLOS ONE paper (open access): a computational study of TP53 mutations in head & neck cancer. hsa-mir-133b is downregulated and linked to poorer survival, and 6 driver mutations weaken DNA binding. doi.org/10.1371/jour...

#bioinformatics #cancergenomics
The impact of mutations on TP53 protein and MicroRNA expression in HNSCC: Novel insights for diagnostic and therapeutic strategies
The tumor suppressor protein p53 (TP53) is frequently mutated in various types of human malignancies, including HNSCC, which affects tumor growth, prognosis, and treatment. Gaining insight into the impact of TP53 mutations in HNSCC is crucial for developing new diagnostic and therapeutic methods. In this study, we aimed to investigate the influence of mutations on the structure and functions of the TP53 protein and miRNA expression using computational analysis. The genomic data of patients with HNSCC were obtained from TCGA, and the impact of mutations on the TP53 gene was investigated using different bioinformatics tools. Results: The findings showed that the TP53 mutations increased TP53 expression levels in HNSCC and were associated with a poor prognosis. Furthermore, hsa-mir-133b expression was reduced in TP53-mutated samples, significantly affecting patient survival in HNSCC. Six mutations, including R273C, G105C, G266E, Q136H/P, and R280G, were identified as deleterious, carcinogenic, driver, highly conserved, and exposed. These mutations were located in the P53 domain, and PTM analysis revealed that R280G and R273C are at a methylation site, and R273C, Q136H/P, and R280G are located in the protein pocket. The docking research indicated that these mutations decreased the binding affinity for DNA, with R273C, R280G, G266E, and G105C displaying the most significant differences. The molecular dynamics analysis indicates that R280G, Q136H, and G105C mutations confer a gain of function by stabilizing the TP53-substrate complex. Conclusions: Based on the research findings, the mutations on TP53 were found to have an impact on protein and miRNA expression, development, survival, and progression of HNSCC patients, and has-mir-133b could be a promising novel biomarker for monitoring the progression of HNSCC. It was discovered that G105C and Q136H/P, as novel mutations, affect the function and structure of proteins causing HNSCC, which indicates that they could be interesting subjects for further investigation, diagnostics, and therapeutic strategies. Furthermore, the precise positioning of R280G and R273C within the methylation site and Q136H/P in the binding site has been documented for the first time. Moreover, the G105C, Q136H, and R280G mutations that stabilized TP53 structure and altered its interaction dynamics with substrates may serve as novel potential diagnostic biomarkers in cancer, guiding patient stratification and personalized treatment strategies. The molecular dynamics analysis provides insights into how specific TP53 mutations impact protein structure, stability, and function upon substrate binding, highlighting their role in cancer biology and potential implications for therapeutic interventions. This paper provides a novel understanding of the mechanisms by which these mutations contribute to the development of cancer.
doi.org
November 11, 2026 at 8:24 PM
A G-Quadruplex Containing First Intron Harbors a Functional Polyadenylation Signal in TP53 https://www.biorxiv.org/content/10.64898/2026.11.08.764788v1
November 11, 2026 at 12:18 PM
A G-Quadruplex Containing First Intron Harbors a Functional Polyadenylation Signal in TP53 https://www.biorxiv.org/content/10.64898/2026.11.08.764788v1
November 11, 2026 at 12:18 PM
Pediatric Li-Fraumeni syndrome surveillance showed high adherence and early TP53 testing, but false positives were common. Urine sampling had the lowest adherence, suggesting future guidelines should balance early detection with burden. bit.ly/48bKuK1
November 10, 2026 at 4:15 PM
Comprehensive Characterization of Somatic Mutations and Gene Expression on TP53/PTEN DKO Murine Glioblastoma Cell Lines: Insights from Whole-Exome and RNA-seq Analysis https://www.biorxiv.org/content/10.64898/2026.11.10.765700v1
November 11, 2026 at 10:45 PM
From the November issue of Cancer Prevention Research: TP53-Mutated Preneoplastic Colonies, Adaptive Immune Response, and Risk for Lung Cancer and COPD buff.ly/GlonH4T
November 11, 2026 at 2:01 AM
Comprehensive Characterization of Somatic Mutations and Gene Expression on TP53/PTEN DKO Murine Glioblastoma Cell Lines: Insights from Whole-Exome and RNA-seq Analysis https://www.biorxiv.org/content/10.64898/2026.11.10.765700v1
November 11, 2026 at 10:45 PM
2/3 Circulating Tumor DNA Profiling Across Phase II/III Ewing Sarcoma Trials Identifies High-Risk Patients With TP53, STAG2, and CDKN2A Alterations.

J Clin Oncol · 4 Nov 2026
doi.org/10.1200/JCO-26-00280
November 10, 2026 at 4:23 PM
Quantum Entanglement as a Physical Determinant of Genomic Instability in TP53 https://www.biorxiv.org/content/10.64898/2026.11.05.764612v1
November 6, 2026 at 8:47 PM
NCI-H1299, the textbook p53-null line, has no TP53 call in DepMap's default sequencing. The check flags it: a homozygous deletion in the curated record, a frameshift in another sequencing of the same model, and a CRISPR readout that behaves as if TP53 were lost.
November 7, 2026 at 10:41 AM
Quantum Entanglement as a Physical Determinant of Genomic Instability in TP53 https://www.biorxiv.org/content/10.64898/2026.11.05.764612v1
November 6, 2026 at 8:47 PM
Is your cell line really wild-type? Most labels only mean a mutation file reported nothing. Our check reads copy number, expression, every sequencing entry, Cellosaurus's curated record and CRISPR readouts against each label. cybergenic.im/cell-lines/check
November 7, 2026 at 10:41 AM
Circulating Tumor DNA Profiling Across Phase II/III Ewing #Sarcoma Trials Identifies High-Risk Patients With TP53, STAG2, and CDKN2A Alterations. ascopubs.org/doi/10.1200/...
Circulating Tumor DNA Profiling Across Phase II/III Ewing Sarcoma Trials Identifies High-Risk Patients With <i>TP53</i>, <i>STAG2</i>, and <i>CDKN2A</i> Alterations
PURPOSEEwing sarcoma is an aggressive bone cancer driven by FET::ETS fusions, with few recurrent secondary genomic alterations (most commonly involving STAG2, TP53, and CDKN2A) and copy-number variant...
ascopubs.org
November 5, 2026 at 10:38 AM
🎗️ 犬猫 腫瘍ニュース — 2026.11.12

🎗️ 犬猫 腫瘍ニュース — 2026.11.12 犬猫の腫瘍・がん関連ニュース&論文 計7件 🎗️ 腫瘍・がん関連ニュース — 2026.11.12 本日 7件 1. 🧬 研究・科学 バーニーズ・マウンテン・ドッグのリンパ腫27検体の遺伝子変異を初めて解析——96.3%に体細胞変異、最多はTRAF3の25.9%、EP300の変異22%は犬種特有の可能性(ミシガン州立大学の検体バンクほか、Veterinary Oncology) 📅 2026.11.05…
🎗️ 犬猫 腫瘍ニュース — 2026.11.12
🎗️ 犬猫 腫瘍ニュース — 2026.11.12 犬猫の腫瘍・がん関連ニュース&論文 計7件 🎗️ 腫瘍・がん関連ニュース — 2026.11.12 本日 7件 1. 🧬 研究・科学 バーニーズ・マウンテン・ドッグのリンパ腫27検体の遺伝子変異を初めて解析——96.3%に体細胞変異、最多はTRAF3の25.9%、EP300の変異22%は犬種特有の可能性(ミシガン州立大学の検体バンクほか、Veterinary Oncology) 📅 2026.11.05 バーニーズ・マウンテン・ドッグは、昔からリンパ腫になりやすい犬種として知られていますが、腫瘍の中でどんな遺伝子変異が起きているのかは明らかではありませんでした。Veterinary Oncology誌に掲載された研究では、ミシガン州立大学の「バーニーズ・マウンテン・ドッグDNA・組織リポジトリ」に保存されていたリンパ腫27検体を、がん関連499遺伝子のパネルで調べました。体細胞変異は27検体中26検体(96.3%)で見つかり、最も多かったのはTRAF3(25.9%)、続いてTP53、EP300、MYC(いずれも22%)、MAP3K14(19%)でした。遺伝子のコピー数の変化(CNV)も27検体中18検体(66%)で確認されています。 著者らは、他の犬種と共通する変化に加え、EP300の変異の多さはこの犬種に特有の特徴かもしれないとし、今後の治療標的や予後の指標の研究につながる可能性があると述べています。一方で、後ろ向きの解析でB細胞性かT細胞性かの区別ができていないこと、検体数が少ないことなど限界も明記されており、より大きな集団での確認が必要です。現時点で飼い主さんの愛犬の治療が変わる段階ではありません。バーニーズを飼っている方は、首や脇、膝の裏などのリンパ節の腫れに日頃から気を配り、しこりに気づいたら早めに獣医師に相談しましょう。 🔗 🧬 研究・科学 2. 🏥 医療・疾病・予防 犬の皮下・筋肉内の血管肉腫53頭に短期間の放射線治療、奏効率93%・全生存期間の中央値306日——放射線の前に手術を受けた犬は中央値2,059日、貧血は予後不良の因子(ワシントン州立大学、Front Vet Sci) 📅 2026.10.06 血管肉腫は、脾臓や心臓だけでなく皮膚の下や筋肉の中にもできることがあり、再発や転移が多いうえ、手術で取りきれないことも少なくありません。ワシントン州立大学のチームはFrontiers in Veterinary Scienceに、皮下または筋肉内の血管肉腫で「寡分割放射線治療」(8Gyを3回、または6Gyを5回の短期間の照射)を受けた犬53頭の後ろ向き研究を報告しました。皮下が27頭、筋肉内が26頭で、照射時に目に見える腫瘍が残っていたのは35頭(66%)、47頭(89%)が抗がん剤も併用していました。評価できた30頭の奏効率は93%(完全奏効37%、部分奏効56%)で、局所の進行・再発は36頭中11頭(30%)でした。全生存期間の中央値は306日で、放射線の前に手術を受けた犬では2,059日、受けなかった犬では287日でした。多変量解析では、貧血のみが死亡リスクの上昇と独立して関連していました(ハザード比3.20)。 著者らは、寡分割放射線治療は多くの場合ほかの治療と組み合わせて行われ、高い奏効率と長期の局所制御が期待できるとしています。副作用は概ね軽度でした。ただし単一施設の後ろ向き研究で治療の選び方にばらつきがあり、手術の有無と腫瘍の大きさ・転移などが互いに絡み合っているため、手術そのものの効果を示したとは言い切れません。皮膚の下に赤黒いしこりやあざのようなふくらみが見つかったら自己判断せず、早めに動物病院で細胞診などの検査を受け、手術や放射線を含む治療の組み合わせを獣医師と相談しましょう。 🔗 🏥 医療・疾病・予防 3. 🧬 研究・科学 パデュー大学、犬の腫瘍を切らずに壊す「アブレーション」の新ラボを開設——集束超音波やパルス電場をCTと超音波ガイドで照射、多くは日帰り、NIHなどが資金提供(パデュー大学) 📅 2026.10.22 米パデュー大学獣医学部は、エバン・アンド・スー・アン・ウェーリング比較腫瘍学研究センターに、犬の腫瘍を対象とした「腫瘍アブレーション」のラボを立ち上げたと発表しました。アブレーションは、狙った場所にエネルギーを当てて腫瘍組織を壊す治療です。CT画像で計画を立て、リアルタイムの超音波で確認しながら、集束超音波やパルス電場を腫瘍に届けます。新しい集束超音波の手法では、顕微鏡レベルの気泡の働きで腫瘍組織を物理的に崩します。多くは日帰りで行える処置とされています。ラボを率いるのは比較腫瘍学のシャウナ・クラーン准教授とニコラオス・デルヴィシス准教授で、2人は10年以上にわたり共同研究を続けてきました。資金はパデュー大学、米国立衛生研究所(NIH)、集束超音波財団が提供しています。 大学は、腫瘍の場所や種類、体の状態によっては、アブレーションが手術や放射線、抗がん剤より効果的な場合があり、健康な組織を残せるため副作用や回復期間が少なくなりうるとしています。腫瘍の周りの免疫環境を変える可能性も研究中ですが、これはまだ証明された結果ではありません。今回の発表は新ラボの紹介で、治療成績の数値は示されていません。犬の膀胱がんや骨のがんは人のがんとよく似ており、犬での研究が人の治療開発にもつながると期待されています。こうした治療は一部の大学病院や臨床試験に限られ、日本での実施状況は不明です。関心がある場合は、かかりつけの獣医師に相談しましょう。 🔗 🧬 研究・科学 4. 🧬 研究・科学 再発した犬のB細胞リンパ腫60頭、薬剤感受性検査の予測に沿った治療で無増悪期間が49日対21日——進行しない1日あたりの費用は117.09ドル対188.53ドルで38%低く(ImpriMed、獣医がん学会で発表)
all-i-need-are-dogs.blog
November 12, 2026 at 12:07 AM
Two checks before a line is called wild-type here: calls on the same reads are rebuilt into one change (HCC2935's EGFR exon 19 deletion arrives in the 25Q3 calls as two frameshifts), and copy number is read (SaOS-2 and Calu-1 have lost TP53, so no TP53 mutation is called).
November 5, 2026 at 12:08 AM
Targeting mutant p53 aggregates in pancreatic cancer using an autophagy-targeting chimera
Protein aggregation is increasingly recognized as a fundamental feature of cancer biology, particularly in tumors experiencing chronic proteotoxic stress. TP53 is one of the most frequently mutated genes in human cancers, and many cancer-associated missense mutations promote p53 misfolding and amyloid-like aggregation. These aggregates impair wild-type tumor-suppressive functions while conferring oncogenic gain-of-function (GOF) activities that promote tumor progression and therapeutic resistance. Despite decades of effort, direct pharmacological targeting of mutant p53 has remained challenging because of its structural properties, including the lack of a readily druggable pocket, as well as its extensive mutational heterogeneity. Here, we employed the AUTOTAC platform to target mutant p53 aggregates by exploiting aggregation-associated conformational features characteristic of β-sheet-rich oligomers and protofibrillar aggregates. ATC-37 was designed by linking a methylene blue-derived amyloid-binding ligand, which preferentially recognizes β-sheet-rich protein aggregates, to an autophagy-targeting ligand (ATL) that allosterically activates the autophagy receptor p62/SQSTM1. This design enables engagement of amyloid-like mutant p53 aggregates and promotes their recruitment to autophagosomes. ATC-37 exhibits a dual, concentration-dependent mechanism of action. At low concentrations, it promotes autophagic degradation of mutant p53 aggregates and suppresses downstream GOF signaling. At higher concentrations, it induces p62-dependent sequestration of mutant p53 aggregates that exceeds autophagic capacity, leading...
www.nature.com
November 7, 2026 at 1:31 PM
Can a cell's own RNA trigger CRISPR to kill it?

In mouse tumor models, activating Cas12a2 by a target transcript enables RNA-triggered chromatin shredding that selectively eliminates cells with mutations in TP53, MYC, and other hard-to-drug cancer genes.

doi.org/10.1158/2159-8290.cd-nw2026-0072
RNA-Triggered Chromatin Shredding Hits Cancer's Hardest Targets.
Cancer Discovery · Covered by 1 news source.
jclub.com.au
November 6, 2026 at 12:09 AM
A lab score for 9,225 TP53 mutations tracked real cancer risk: in 437 people with Li-Fraumeni syndrome, high-scoring variants were associated with earlier cancer.

@ajhgnews.bsky.social

👇 Link to the full episode in the first reply.
November 5, 2026 at 3:05 PM
🧬New today!
📄Deep #CRISPR mutagenesis predicts cancer risk in Li-Fraumeni syndrome
Deep CRISPR mutagenesis predicts cancer risk in Li-Fraumeni syndrome
TP53 encodes for the transcription factor TP53, which controls the expression of genes involved in cell cycle, apoptosis, senescence, stem cell differentiation, metabolism, and DNA repair.1 ∼50% of al...
www.cell.com
November 2, 2026 at 5:40 PM
www.findaphd.com/phds/project....

Interested in a PhD?- are you a medical student? TP53-mutant acute erythroid leukaemia is among the most difficult cancers to treat and may rely on surrounding cells for survival.
November 2, 2026 at 9:52 AM
Or build your own list: name what a line must carry, the genes it must lack (no mutation called, no loss in copy number) and a cancer type, then download the lines that fit. cybergenic.im/cell-lines/finder
Cell line finder: cancer cell lines by mutation | Cybergenic
Find cancer cell lines by what they carry and what they lack: a gene, a change or a class (KRAS G12C, EGFR exon 19 deletions), a gene with no mutation called (TP53, STK11), a cancer type. 1,640 lines ...
cybergenic.im
November 5, 2026 at 12:07 AM
APR-246 and DNA polymerase theta inhibitor Novobiocinsynergize to eliminate TP53 mutant AML cells https://www.biorxiv.org/content/10.64898/2026.10.30.763043v1
November 2, 2026 at 6:46 PM